Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: In vivo administration of urolithin A and B prevents the occurrence of cardiac dysfunction in streptozotocin-induced diabetic rats

Fig. 2

Hemodynamic measurements. Mean values ± SEM of left ventricular systolic pressure (LVSP; a), left ventricular end diastolic pressure (LVEDP; b), maximal rate of ventricular pressure rise (+dP/dtmax; c), and decline (−dP/dtmax; d), isovolumic contraction time (IVCT; e), and total cycle duration (Tcycle; f), measured in control rats (CTRL, n = 10), untreated diabetic rats (D3, n = 9), and urolithin A-treated (D3-UA, n = 10) or urolithin B-treated (D3-UB, n = 10) diabetic animals. *p < 0.05 significant differences vs CTRL; # p < 0.05 significant differences vs D3 (two-way ANOVA)

Back to article page